Washington University School of Medicine
The blood brain barrier (BBB) is a major obstacle to drug delivery in the treatment of malignant brain tumors including Glioblastoma multiforme (GBM). MRI-guided laser ablation (MLA) has been noted to disrupt peritumoral BBB, which could then lead to increased access of new tumor antigens to the lymphovascular system and vice versa of immune effector cells to the tumor for effective activation of the immune system. Therefore the combination of MK-3475 and MLA as proposed in this protocol is hypothesized to create a therapeutic synergy in which MLA increases material access to promote immune activation and then MK-3475 maximizes these tumor-specific immune reactions to impart effective tumor control.
Malignant Glioma
MK-3475
MRI-guided laser ablation
Surgical resection/debulking
Biopsy
Blood draw for research purposes
Cervical lymph node fine needle aspiration
PHASE1
PHASE2
Study Type : | INTERVENTIONAL |
Estimated Enrollment : | 55 participants |
Masking : | NONE |
Primary Purpose : | TREATMENT |
Official Title : | A Phase I/II Study Testing the Safety, Toxicities, and Efficacy of MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas |
Actual Study Start Date : | 2015-08-05 |
Estimated Primary Completion Date : | 2024-04-15 |
Estimated Study Completion Date : | 2024-04-15 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
University of Florida
Gainesville, florida, United States, 32611
Not yet recruiting
Washington University School of Medicine
St. Louis, Missouri, United States, 63110